Robeco Institutional Asset Management B.V. Raises Holdings in Maximus, Inc. $MMS

Robeco Institutional Asset Management B.V. increased its stake in shares of Maximus, Inc. (NYSE:MMS) by 64.0% during the 3rd quarter, Holdings Channel reports. The fund owned 29,644 shares of the health services provider’s stock after purchasing an additional 11,567 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Maximus were worth $2,709,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Canada Pension Plan Investment Board acquired a new position in shares of Maximus in the 2nd quarter valued at $35,000. UMB Bank n.a. grew its position in Maximus by 37.5% during the second quarter. UMB Bank n.a. now owns 833 shares of the health services provider’s stock valued at $58,000 after buying an additional 227 shares during the period. Bayforest Capital Ltd purchased a new position in Maximus in the second quarter valued at $61,000. Parkside Financial Bank & Trust increased its stake in shares of Maximus by 21.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 879 shares of the health services provider’s stock valued at $62,000 after purchasing an additional 157 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Maximus by 60.4% in the second quarter. GAMMA Investing LLC now owns 1,174 shares of the health services provider’s stock valued at $82,000 after purchasing an additional 442 shares during the period. Institutional investors and hedge funds own 97.21% of the company’s stock.

Maximus Trading Up 2.2%

NYSE:MMS opened at $97.00 on Friday. Maximus, Inc. has a 1 year low of $63.77 and a 1 year high of $97.20. The stock has a market cap of $5.28 billion, a P/E ratio of 17.45 and a beta of 0.56. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.64 and a current ratio of 1.64. The stock has a 50-day simple moving average of $85.50 and a 200-day simple moving average of $83.26.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.01). Maximus had a return on equity of 25.23% and a net margin of 5.87%.The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.34 billion. During the same period last year, the business posted $1.46 EPS. Maximus’s revenue was up .2% on a year-over-year basis. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. As a group, analysts anticipate that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a $0.33 dividend. This is a boost from Maximus’s previous quarterly dividend of $0.30. This represents a $1.32 annualized dividend and a yield of 1.4%. The ex-dividend date is Friday, February 13th. Maximus’s payout ratio is currently 23.74%.

Insider Activity

In other news, insider Michelle F. Link sold 4,039 shares of Maximus stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $86.84, for a total transaction of $350,746.76. Following the sale, the insider owned 19,542 shares in the company, valued at approximately $1,697,027.28. The trade was a 17.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on MMS. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Maximus in a report on Monday, December 29th. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat, Maximus presently has a consensus rating of “Strong Buy”.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.